{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T09:26:31Z","timestamp":1781083591349,"version":"3.54.1"},"reference-count":16,"publisher":"SAGE Publications","issue":"5","license":[{"start":{"date-parts":[[2016,7,9]],"date-time":"2016-07-09T00:00:00Z","timestamp":1468022400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Int J Toxicol"],"published-print":{"date-parts":[[2016,9]]},"abstract":"<jats:p>Lanthionine synthetase cyclase-like receptor 2 (LANCL2) is a novel therapeutic target for Crohn\u2019s disease (CD). BT-11 is a small molecule that binds LANCL2, is orally active, and has demonstrated therapeutic efficacy in 3 validated mouse models of colitis at doses as low as 8 mg\/kg\/d. Exploratory experiments evaluated BT-11 in male Harlan Sprague Dawley rats with a single oral dose of 500 mg\/kg and 80 mg\/kg\/d for 14 days (n = 10 rats dosed\/group). Treated and control rats were observed for behavioral detriments, and blood and tissues were collected for clinical pathology and histopathological examination. A functional observational battery demonstrated no differences between treated and control groups over multiple times of observation for quantal, categorical, and continuous end points, including posture, in cage activity, approach, response to touch, weight, grip strength, body temperature, and time on a rotarod. Histopathological examination of the brain, kidney, liver, adrenal gland, testes, stomach, small and large intestines, duodenum, pancreas, heart, lungs, spleen, thymus, and rib found no significant differences between the groups. Plasma enzymes associated with liver function were transiently elevated 2 to 4 days after the 500 mg\/kg single dose but returned to normal values by 8 days and were not observed at any time in rats given 80 mg\/kg\/d for 14 days. One hour after oral administration of a single dose of 80 mg\/kg, BT-11 had a maximal concentration of 21 ng\/mL; the half-life was 3 hours. These experimental results demonstrated that BT-11 is well tolerated in rats, and, with further testing, may hold promise as an orally active therapeutic for CD.<\/jats:p>","DOI":"10.1177\/1091581816646356","type":"journal-article","created":{"date-parts":[[2016,5,26]],"date-time":"2016-05-26T21:20:06Z","timestamp":1464297606000},"page":"521-529","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":18,"title":["Exploratory Studies With BT-11"],"prefix":"10.1177","volume":"35","author":[{"given":"Philippe","family":"Bissel","sequence":"first","affiliation":[{"name":"Virginia\u2013Maryland College of Veterinary Medicine, Virginia Tech, Blacksburg, VA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katie","family":"Boes","sequence":"additional","affiliation":[{"name":"Virginia\u2013Maryland College of Veterinary Medicine, Virginia Tech, Blacksburg, VA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Hinckley","sequence":"additional","affiliation":[{"name":"Virginia\u2013Maryland College of Veterinary Medicine, Virginia Tech, Blacksburg, VA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernard S.","family":"Jortner","sequence":"additional","affiliation":[{"name":"Virginia\u2013Maryland College of Veterinary Medicine, Virginia Tech, Blacksburg, VA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geraldine","family":"Magnin-Bissel","sequence":"additional","affiliation":[{"name":"Virginia\u2013Maryland College of Veterinary Medicine, Virginia Tech, Blacksburg, VA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen R.","family":"Werre","sequence":"additional","affiliation":[{"name":"Virginia\u2013Maryland College of Veterinary Medicine, Virginia Tech, Blacksburg, VA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marion","family":"Ehrich","sequence":"additional","affiliation":[{"name":"Virginia\u2013Maryland College of Veterinary Medicine, Virginia Tech, Blacksburg, VA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adria","family":"Carbo","sequence":"additional","affiliation":[{"name":"Biotherapeutics Inc, Blacksburg, VA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Casandra","family":"Philipson","sequence":"additional","affiliation":[{"name":"Biotherapeutics Inc, Blacksburg, VA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raquel","family":"Hontecillas","sequence":"additional","affiliation":[{"name":"Biotherapeutics Inc, Blacksburg, VA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noah","family":"Philipson","sequence":"additional","affiliation":[{"name":"Biotherapeutics Inc, Blacksburg, VA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard D.","family":"Gandour","sequence":"additional","affiliation":[{"name":"Biotherapeutics Inc, Blacksburg, VA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josep","family":"Bassaganya-Riera","sequence":"additional","affiliation":[{"name":"Biotherapeutics Inc, Blacksburg, VA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2016,7,9]]},"reference":[{"key":"bibr1-1091581816646356","doi-asserted-by":"publisher","DOI":"10.1016\/0016-5085(95)90034-9"},{"key":"bibr2-1091581816646356","volume-title":"Cancer Epidemiology in Older Adolescents and Young Adults 15 to 29 Years of Age, Including SEER Incidence and Survival: 1975\u20132000","author":"Bleyer A","year":"2006"},{"key":"bibr3-1091581816646356","doi-asserted-by":"publisher","DOI":"10.1016\/S1542-3565(03)00220-9"},{"key":"bibr4-1091581816646356","volume-title":"Recent Advances in the Treatment of Crohn\u2019s Colitis","author":"Lichtenstein GR","year":"2003"},{"key":"bibr5-1091581816646356","first-page":"1351","volume-title":"Goodman & Gilman\u2019s: The Pharmacological Basis of Therapeutics","author":"Wallace JL","year":"2011","edition":"12"},{"key":"bibr6-1091581816646356","doi-asserted-by":"publisher","DOI":"10.2174\/1389450115666140313123714"},{"key":"bibr7-1091581816646356","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M110.160077"},{"key":"bibr8-1091581816646356","unstructured":"PubChem Chemical Information. Web site. http:\/\/pubchem.ncbi.nlm.nih.gov\/compound\/247228#section=Top. Accessed April 26, 2016."},{"key":"bibr9-1091581816646356","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5085(15)32321-0"},{"key":"bibr10-1091581816646356","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0034643"},{"key":"bibr11-1091581816646356","doi-asserted-by":"publisher","DOI":"10.1016\/B978-0-12-387815-1.00005-8"},{"key":"bibr12-1091581816646356","unstructured":"Food and Drug Administration Center for Drug Evaluation and Research (FDA CDER). Guidance for industry M3(R2) nonclinical safety studies for the conduct of human clinical trials and marketing authorization for pharmaceuticals. 2010. Web site. http:\/\/www.fda.gov\/downloads\/drugs\/guidancecomplianceregulatoryinformation\/guidances\/ucm073246.pdf. Accessed April 26, 2016."},{"key":"bibr13-1091581816646356","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmpb.2010.01.007"},{"key":"bibr14-1091581816646356","first-page":"11.2.1","volume-title":"Current Protocols in Toxicology","author":"Moser VC","year":"1999"},{"key":"bibr15-1091581816646356","first-page":"41","volume-title":"Basic & Clinical Pharmacology","author":"Holford NHG","year":"2015","edition":"13"},{"key":"bibr16-1091581816646356","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejps.2007.05.110"}],"container-title":["International Journal of Toxicology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1091581816646356","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/1091581816646356","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1091581816646356","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T10:25:00Z","timestamp":1777458300000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/1091581816646356"}},"subtitle":["A Proposed Orally Active Therapeutic for Crohn\u2019s Disease"],"short-title":[],"issued":{"date-parts":[[2016,7,9]]},"references-count":16,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2016,9]]}},"alternative-id":["10.1177\/1091581816646356"],"URL":"https:\/\/doi.org\/10.1177\/1091581816646356","relation":{},"ISSN":["1091-5818","1092-874X"],"issn-type":[{"value":"1091-5818","type":"print"},{"value":"1092-874X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,7,9]]}}}